King's College London

Research portal

Clopidogrel as prophylactic treatment for migraine: A pilot randomised, controlled study

Research output: Contribution to journalArticle

Standard

Clopidogrel as prophylactic treatment for migraine : A pilot randomised, controlled study. / Chambers, John B; Seed, Paul T; Ridsdale, Leone.

In: Cephalalgia, Vol. 34, No. 14, 2014, p. 1163-1168.

Research output: Contribution to journalArticle

Harvard

Chambers, JB, Seed, PT & Ridsdale, L 2014, 'Clopidogrel as prophylactic treatment for migraine: A pilot randomised, controlled study', Cephalalgia, vol. 34, no. 14, pp. 1163-1168. https://doi.org/10.1177/0333102414531156

APA

Chambers, J. B., Seed, P. T., & Ridsdale, L. (2014). Clopidogrel as prophylactic treatment for migraine: A pilot randomised, controlled study. Cephalalgia, 34(14), 1163-1168. https://doi.org/10.1177/0333102414531156

Vancouver

Chambers JB, Seed PT, Ridsdale L. Clopidogrel as prophylactic treatment for migraine: A pilot randomised, controlled study. Cephalalgia. 2014;34(14):1163-1168. https://doi.org/10.1177/0333102414531156

Author

Chambers, John B ; Seed, Paul T ; Ridsdale, Leone. / Clopidogrel as prophylactic treatment for migraine : A pilot randomised, controlled study. In: Cephalalgia. 2014 ; Vol. 34, No. 14. pp. 1163-1168.

Bibtex Download

@article{3fc6823d2ce140959ecb945993f0fed3,
title = "Clopidogrel as prophylactic treatment for migraine: A pilot randomised, controlled study",
abstract = "Introduction: Anecdotal reports suggest that clopidogrel may prevent migraine attacks. We undertook a pilot randomised trial.Method: We randomised consecutive migraineurs with four to 15 headache days per 28-day month to receive clopidogrel 75 mg or placebo daily for three months. Headache was primarily assessed with a headache diary.Results: There were no statistically significant treatment effects. The number of headache days fell by 1.9 on clopidogrel and 1.6 on placebo (adjusted difference 0.02, CI −2.07 to 2.12). Headache severity rose by 0.14 points (out of 10) on clopidogrel, and fell by 0.63 on placebo; treatment effect 0.7 points (CI −0.11 to 1.57). The main treatment effect did not depend on the presence or absence of migraine with aura at baseline, a patent foramen ovale (PFO) or atrial septal aneurysm.Discussion: The evidence is inconclusive, but a multicentre trial would be feasible recruiting from primary care.",
author = "Chambers, {John B} and Seed, {Paul T} and Leone Ridsdale",
year = "2014",
doi = "10.1177/0333102414531156",
language = "English",
volume = "34",
pages = "1163--1168",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "14",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Clopidogrel as prophylactic treatment for migraine

T2 - A pilot randomised, controlled study

AU - Chambers, John B

AU - Seed, Paul T

AU - Ridsdale, Leone

PY - 2014

Y1 - 2014

N2 - Introduction: Anecdotal reports suggest that clopidogrel may prevent migraine attacks. We undertook a pilot randomised trial.Method: We randomised consecutive migraineurs with four to 15 headache days per 28-day month to receive clopidogrel 75 mg or placebo daily for three months. Headache was primarily assessed with a headache diary.Results: There were no statistically significant treatment effects. The number of headache days fell by 1.9 on clopidogrel and 1.6 on placebo (adjusted difference 0.02, CI −2.07 to 2.12). Headache severity rose by 0.14 points (out of 10) on clopidogrel, and fell by 0.63 on placebo; treatment effect 0.7 points (CI −0.11 to 1.57). The main treatment effect did not depend on the presence or absence of migraine with aura at baseline, a patent foramen ovale (PFO) or atrial septal aneurysm.Discussion: The evidence is inconclusive, but a multicentre trial would be feasible recruiting from primary care.

AB - Introduction: Anecdotal reports suggest that clopidogrel may prevent migraine attacks. We undertook a pilot randomised trial.Method: We randomised consecutive migraineurs with four to 15 headache days per 28-day month to receive clopidogrel 75 mg or placebo daily for three months. Headache was primarily assessed with a headache diary.Results: There were no statistically significant treatment effects. The number of headache days fell by 1.9 on clopidogrel and 1.6 on placebo (adjusted difference 0.02, CI −2.07 to 2.12). Headache severity rose by 0.14 points (out of 10) on clopidogrel, and fell by 0.63 on placebo; treatment effect 0.7 points (CI −0.11 to 1.57). The main treatment effect did not depend on the presence or absence of migraine with aura at baseline, a patent foramen ovale (PFO) or atrial septal aneurysm.Discussion: The evidence is inconclusive, but a multicentre trial would be feasible recruiting from primary care.

U2 - 10.1177/0333102414531156

DO - 10.1177/0333102414531156

M3 - Article

C2 - 24836213

VL - 34

SP - 1163

EP - 1168

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 14

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454